GSK

News

Alfasigma licenses liver drug from GSK in $690m deal

With an FDA verdict looming, GSK has signed an eleventh-hour deal to give Alfasigma rights to its primary biliary cholangitis therapy linerixibat.

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

News

EU approval for new asthma drug Exdensur lifts GSK

EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur.

News

GSK delivers in new CEO Miels' first financial update

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits.

News

GSK departs Wave's AATD programme

Wave Life Sciences has lost GSK as the partner for its alpha-1 antitrypsin deficiency drug, but other partnered RNA-editing programmes remain active.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

Alfasigma licenses liver drug from GSK in $690m deal

GSK grows pipeline with 35Pharma takeover, Frontier deal

EU approval for new asthma drug Exdensur lifts GSK

GSK delivers in new CEO Miels' first financial update

GSK departs Wave's AATD programme

CMS's Medicare price negotiations start round three

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks